ArticleAAPS PharmSciTech2018
Mixed Liposome Approach for Ratiometric and Sequential Delivery of Paclitaxel and Gemcitabine.
Article in AAPS PharmSciTech, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Nanocarrier drug delivery systems for gynecological cancer therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2025Review
- Co-Encapsulation of Multiple Antineoplastic Agents in Liposomes by Exploring Microfluidics.International journal of molecular sciences · 2025Review
- Advanced Targeted Drug Delivery of Bioactive Nanomaterials in the Management of Cancer.Current medicinal chemistry · 2025Review
- Polymer Conjugate as the New Promising Drug Delivery System for Combination Therapy against Cancer.Current topics in medicinal chemistry · 2024Review
- Fine-tuning the sequential drug release of nano-formulated mutual prodrugs dictates the combination effects.Chemical science · 2023Article
- Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine-Combination Therapy.Nanomaterials (Basel, Switzerland) · 2021Review
- Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models.International journal of pharmaceutics: X · 2020Article
- A review of research progress of antitumor drugs based on tubulin targets.Translational cancer research · 2020Review
- A solvent-assisted active loading technology to prepare gambogic acid and all-trans retinoic acid co-encapsulated liposomes for synergistic anticancer therapy.Drug delivery and translational research · 2020Article
- Phospholipid prodrug conjugates of insoluble chemotherapeutic agents for ultrasound targeted drug delivery.Nanotheranostics · 2020Article
- Gemcitabine Combination Nano Therapies for Pancreatic Cancer.Pharmaceutics · 2019Review
- Tumor-specific delivery of gemcitabine with activatable liposomes.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Development of Liposomal Gemcitabine with High Drug Loading Capacity.Molecular pharmaceutics · 2019Article
- Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment.Molecules (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Paclitaxel (PTX) and gemcitabine (GEM) are often used in combination due to the synergistic anticancer effects. PTX and GEM combination showed a synergistic effect to SKOV-3 cells at a molar ratio of 1 to 1 and in PTX ➔ GEM sequence. Liposomes were explored as a carrier of PTX and GEM combination. We optimized the drug loading in liposomes varying the preparation method and co-encapsulated PTX and GEM in a single liposome preparation maintaining the maximum loading efficiency of each drug. However, drug release kinetics from the co-loaded liposomes (LpPG) was suboptimal because of the detrimental effect of PTX on GEM-release control. Instead, a mixture of LpP and LpG, which were separately optimized according to the desired release kinetics, achieved a greater cytotoxic effect than LpPG, due to the attenuation of GEM release relative to PTX. This study illustrates that co-encapsulation in a single carrier is not always desirable for the delivery of drug combinations, when the activity depends on the dosing sequence. These combinations may benefit from the mixed liposome approach, which offers greater flexibility in controlling the ratio and release kinetics of component drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.